Development of a novel albumin-binding prodrug that is cleaved by urokinase-type-plasminogen activator (uPA).
A water-soluble albumin-binding prodrug of doxorubicin [EMC-Gly-Gly-Gly-Arg-Arg-DOXO (EMC, 6-maleimidocaproic acid)] was developed that is cleaved specifically by the tumor-associated protease urokinase-type plasminogen activator (uPA).
Chung
Da-Eun
DE
Tumor Biology Center, Breisacher Strasse 117, 79106 Freiburg, Germany.
Kratz
Felix
F
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004317:Doxorubicin / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D016503:Drug Delivery Systems; D006801:Humans; D011355:Prodrugs / Q000378:metabolism* / Q000493:pharmacokinetics; D011485:Protein Binding; D012709:Serum Albumin / Q000378:metabolism*; D012995:Solubility; D013329:Structure-Activity Relationship; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism*
D000970:Antineoplastic Agents; D011355:Prodrugs; D012709:Serum Albumin; D004317:Doxorubicin; D014568:Urokinase-Type Plasminogen Activator